Celldex Therapeutics(CLDX)
HAMPTON, NJBiotechnology
Focus: Celldex is a mid-cap public biotech focused on small molecules, biologics, and vaccines across infectious diseases and oncology. With ~750 employees and a diversified pipeline of 30 programs, the company is transitioning from pre-commercial to early commercial stage.
Profile data last refreshed 15h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Employees
501-1000
Open Jobs
20
Should You Work at Celldex Therapeutics?
AI assessmentCelldex suits risk-tolerant professionals seeking deep pipeline involvement and equity upside in a pre-commercial biotech, but requires comfort with high cash burn and clinical-stage uncertainty.
Why Work Here
- Lead a high-risk, high-reward pipeline with multiple Phase 3 programs (Barzolvolimab in urticaria recently showed positive Phase 3 results per Sept 2026 news), offering early-stage drug development exposure.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$7M
Pipeline & Clinical Trials
glembatumumab vedotin
Metastatic gpNMB Expressing Triple Negative Breast CancerClinical Trials (1)
NCT03067935Individual Patient Expanded Access-Glembatumumab Vedotin
N/AHelp build intelligence for Celldex Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.